Complement in action: An analysis of patent trends from 1976 through 2011

Kun Yang, Robert A. Deangelis, Janet E. Reed, Daniel Ricklin, John D. Lambris

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Complement is an essential part of the innate immune response. It interacts with diverse endogenous pathways and contributes to the maintenance of homeostasis, the modulation of adaptive immune responses, and the development of various pathologies. The potential usefulness, in both research and clinical settings, of compounds that detect or modulate complement activity has resulted in thousands of publications on complement-related innovations in fields such as drug discovery, disease diagnosis and treatment, and immunoassays, among others. This study highlights the distribution and publication trends of patents related to the complement system that were granted by the United States Patent and Trademark Office from 1976 to the present day. A comparison to complement-related documents published by the World Intellectual Property Organization is also included. Statistical analyses revealed increasing diversity in complement-related research interests over time. More than half of the patents were found to focus on the discovery of inhibitors; interest in various inhibitor classes exhibited a remarkable transformation from chemical compounds early on to proteins and antibodies in more recent years. Among clinical applications, complement proteins and their modulators have been extensively patented for the diagnosis and treatment of eye diseases (especially age-related macular degeneration), graft rejection, cancer, sepsis, and a variety of other inflammatory and immune diseases. All of the patents discussed in this chapter, as well as those from other databases, are available from our newly constructed complement patent database: www.innateimmunity.us/patent.

Original languageEnglish (US)
Title of host publicationComplement Therapeutics
PublisherSpringer New York LLC
Pages301-313
Number of pages13
Volume734
ISBN (Print)9781461441175
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume734
ISSN (Print)0065-2598

Fingerprint

Patents
Publications
Trademarks
Chemical compounds
Intellectual property
Databases
Pathology
Intellectual Property
Grafts
Modulators
Eye Diseases
Immune System Diseases
Complement System Proteins
Macular Degeneration
Graft Rejection
Adaptive Immunity
Drug Discovery
Innovation
Immunoassay
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yang, K., Deangelis, R. A., Reed, J. E., Ricklin, D., & Lambris, J. D. (2013). Complement in action: An analysis of patent trends from 1976 through 2011. In Complement Therapeutics (Vol. 734, pp. 301-313). (Advances in Experimental Medicine and Biology; Vol. 734). Springer New York LLC. https://doi.org/10.1007/978-1-4614-4118-2_21

Complement in action : An analysis of patent trends from 1976 through 2011. / Yang, Kun; Deangelis, Robert A.; Reed, Janet E.; Ricklin, Daniel; Lambris, John D.

Complement Therapeutics. Vol. 734 Springer New York LLC, 2013. p. 301-313 (Advances in Experimental Medicine and Biology; Vol. 734).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Yang, K, Deangelis, RA, Reed, JE, Ricklin, D & Lambris, JD 2013, Complement in action: An analysis of patent trends from 1976 through 2011. in Complement Therapeutics. vol. 734, Advances in Experimental Medicine and Biology, vol. 734, Springer New York LLC, pp. 301-313. https://doi.org/10.1007/978-1-4614-4118-2_21
Yang K, Deangelis RA, Reed JE, Ricklin D, Lambris JD. Complement in action: An analysis of patent trends from 1976 through 2011. In Complement Therapeutics. Vol. 734. Springer New York LLC. 2013. p. 301-313. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4614-4118-2_21
Yang, Kun ; Deangelis, Robert A. ; Reed, Janet E. ; Ricklin, Daniel ; Lambris, John D. / Complement in action : An analysis of patent trends from 1976 through 2011. Complement Therapeutics. Vol. 734 Springer New York LLC, 2013. pp. 301-313 (Advances in Experimental Medicine and Biology).
@inproceedings{e4d9766731bb4faea185169b1798143c,
title = "Complement in action: An analysis of patent trends from 1976 through 2011",
abstract = "Complement is an essential part of the innate immune response. It interacts with diverse endogenous pathways and contributes to the maintenance of homeostasis, the modulation of adaptive immune responses, and the development of various pathologies. The potential usefulness, in both research and clinical settings, of compounds that detect or modulate complement activity has resulted in thousands of publications on complement-related innovations in fields such as drug discovery, disease diagnosis and treatment, and immunoassays, among others. This study highlights the distribution and publication trends of patents related to the complement system that were granted by the United States Patent and Trademark Office from 1976 to the present day. A comparison to complement-related documents published by the World Intellectual Property Organization is also included. Statistical analyses revealed increasing diversity in complement-related research interests over time. More than half of the patents were found to focus on the discovery of inhibitors; interest in various inhibitor classes exhibited a remarkable transformation from chemical compounds early on to proteins and antibodies in more recent years. Among clinical applications, complement proteins and their modulators have been extensively patented for the diagnosis and treatment of eye diseases (especially age-related macular degeneration), graft rejection, cancer, sepsis, and a variety of other inflammatory and immune diseases. All of the patents discussed in this chapter, as well as those from other databases, are available from our newly constructed complement patent database: www.innateimmunity.us/patent.",
author = "Kun Yang and Deangelis, {Robert A.} and Reed, {Janet E.} and Daniel Ricklin and Lambris, {John D.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-4118-2_21",
language = "English (US)",
isbn = "9781461441175",
volume = "734",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "301--313",
booktitle = "Complement Therapeutics",

}

TY - GEN

T1 - Complement in action

T2 - An analysis of patent trends from 1976 through 2011

AU - Yang, Kun

AU - Deangelis, Robert A.

AU - Reed, Janet E.

AU - Ricklin, Daniel

AU - Lambris, John D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Complement is an essential part of the innate immune response. It interacts with diverse endogenous pathways and contributes to the maintenance of homeostasis, the modulation of adaptive immune responses, and the development of various pathologies. The potential usefulness, in both research and clinical settings, of compounds that detect or modulate complement activity has resulted in thousands of publications on complement-related innovations in fields such as drug discovery, disease diagnosis and treatment, and immunoassays, among others. This study highlights the distribution and publication trends of patents related to the complement system that were granted by the United States Patent and Trademark Office from 1976 to the present day. A comparison to complement-related documents published by the World Intellectual Property Organization is also included. Statistical analyses revealed increasing diversity in complement-related research interests over time. More than half of the patents were found to focus on the discovery of inhibitors; interest in various inhibitor classes exhibited a remarkable transformation from chemical compounds early on to proteins and antibodies in more recent years. Among clinical applications, complement proteins and their modulators have been extensively patented for the diagnosis and treatment of eye diseases (especially age-related macular degeneration), graft rejection, cancer, sepsis, and a variety of other inflammatory and immune diseases. All of the patents discussed in this chapter, as well as those from other databases, are available from our newly constructed complement patent database: www.innateimmunity.us/patent.

AB - Complement is an essential part of the innate immune response. It interacts with diverse endogenous pathways and contributes to the maintenance of homeostasis, the modulation of adaptive immune responses, and the development of various pathologies. The potential usefulness, in both research and clinical settings, of compounds that detect or modulate complement activity has resulted in thousands of publications on complement-related innovations in fields such as drug discovery, disease diagnosis and treatment, and immunoassays, among others. This study highlights the distribution and publication trends of patents related to the complement system that were granted by the United States Patent and Trademark Office from 1976 to the present day. A comparison to complement-related documents published by the World Intellectual Property Organization is also included. Statistical analyses revealed increasing diversity in complement-related research interests over time. More than half of the patents were found to focus on the discovery of inhibitors; interest in various inhibitor classes exhibited a remarkable transformation from chemical compounds early on to proteins and antibodies in more recent years. Among clinical applications, complement proteins and their modulators have been extensively patented for the diagnosis and treatment of eye diseases (especially age-related macular degeneration), graft rejection, cancer, sepsis, and a variety of other inflammatory and immune diseases. All of the patents discussed in this chapter, as well as those from other databases, are available from our newly constructed complement patent database: www.innateimmunity.us/patent.

UR - http://www.scopus.com/inward/record.url?scp=84934440319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934440319&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4118-2_21

DO - 10.1007/978-1-4614-4118-2_21

M3 - Conference contribution

C2 - 23402036

AN - SCOPUS:84934440319

SN - 9781461441175

VL - 734

T3 - Advances in Experimental Medicine and Biology

SP - 301

EP - 313

BT - Complement Therapeutics

PB - Springer New York LLC

ER -